skip to main content

Valproate reproductive safety — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TherapeuticsValproate reproductive safetyGPhC CRA

A 24-year-old woman with epilepsy presents a repeat for sodium valproate 500 mg twice daily. She says she is planning pregnancy next year and has not discussed contraception or alternatives recently. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CSupply if clinically appropriate but urgently refer to prescriber for specialist review and Pregnancy Prevention Programme discussion

Valproate is highly teratogenic and subject to strict risk minimisation measures. Abrupt discontinuation can cause seizures and should not be advised without specialist input. The pharmacist should ensure the patient receives current warnings and prompt prescriber or specialist review regarding contraception and alternatives. This balances immediate seizure safety with reproductive risk.

Reference: BNF; MHRA Drug Safety Update